{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:13:35Z","timestamp":1782789215164,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Health Canada Substance Use and Addictions Program","award":["1920-HQ-000031"],"award-info":[{"award-number":["1920-HQ-000031"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40258-022-00787-0","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T11:02:57Z","timestamp":1674039777000},"page":"501-510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Impact of Suboxone\u2019s Market Exclusivity on Cost of Opioid Use Disorder Treatment"],"prefix":"10.1007","volume":"21","author":[{"given":"Meghan","family":"McGee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellia","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahim","family":"Moineddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8354-6153","authenticated-orcid":false,"given":"Abhimanyu","family":"Sud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"787_CR1","unstructured":"Centre for Addiction and Mental Health. Opioid agonist therapy: a synthesis of Canadian guidelines for treating opioid use disorder. 2021."},{"key":"787_CR2","first-page":"22439","volume":"86","author":"Health and Human Services Department","year":"2021","unstructured":"Health and Human Services Department. Practice guidelines for the administration of buprenorphine for treating opioid use disorder. Fed Reg. 2021;86:22439\u201340.","journal-title":"Fed Reg"},{"key":"787_CR3","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:1550. https:\/\/doi.org\/10.1136\/bmj.j1550.","journal-title":"BMJ"},{"key":"787_CR4","unstructured":"Health Canada. Surveillance of opioid- and stimulant-related harms in Canada. 2021."},{"key":"787_CR5","unstructured":"Ahamad K, Kerr T, Nolan S, Wood E. Moving towards improved access for evidence-based opioid addiction care in British Columbia. 2016."},{"key":"787_CR6","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","volume":"35","author":"K Mackey","year":"2020","unstructured":"Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Barriers and facilitators to the use of medications for opioid use disorder: a rapid review. J Gen Intern Med. 2020;35:954\u201363. https:\/\/doi.org\/10.1007\/s11606-020-06257-4.","journal-title":"J Gen Intern Med"},{"key":"787_CR7","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/j.1468-0327.2008.00207.x","volume":"23","author":"P Kanavos","year":"2008","unstructured":"Kanavos P, Costa-Font J, Seeley E. Competition in off-patent drug markets: Issues, regulation and evidence. Econ Policy. 2008;23:500\u201344. https:\/\/doi.org\/10.1111\/j.1468-0327.2008.00207.x.","journal-title":"Econ Policy"},{"key":"787_CR8","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.jval.2017.05.004","volume":"20","author":"J Lexchin","year":"2017","unstructured":"Lexchin J. Market exclusivity time for top selling originator drugs in Canada: a cohort study. Value Health. 2017;20:1139\u201342. https:\/\/doi.org\/10.1016\/j.jval.2017.05.004.","journal-title":"Value Health"},{"key":"787_CR9","doi-asserted-by":"publisher","first-page":"103749","DOI":"10.1016\/j.drugpo.2022.103749","volume":"105","author":"A Sud","year":"2022","unstructured":"Sud A, McGee M, Mintzes B, Herder M. Permissive regulation: a critical review of the regulatory history of buprenorphine formulations in Canada. Int J Drug Policy. 2022;105:103749. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103749.","journal-title":"Int J Drug Policy"},{"key":"787_CR10","doi-asserted-by":"publisher","DOI":"10.34172\/ijhpm.2020.215","author":"W Zhang","year":"2020","unstructured":"Zhang W, Sun H, Guh DP, Lynd LD, Hollis A, Grootendorst P, et al. The impact of tiered-pricing framework on generic entry in Canada. Int J Health Policy Manag. 2020. https:\/\/doi.org\/10.34172\/ijhpm.2020.215.","journal-title":"Int J Health Policy Manag"},{"key":"787_CR11","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1503\/cmaj.150395","volume":"187","author":"A Hollis","year":"2015","unstructured":"Hollis A. Generic drugs in Canada: an examination of tiered pricing. CMAJ. 2015;187:1033\u20134. https:\/\/doi.org\/10.1503\/cmaj.150395.","journal-title":"CMAJ"},{"key":"787_CR12","doi-asserted-by":"publisher","first-page":"e221096","DOI":"10.1001\/jamahealthforum.2022.1096","volume":"3","author":"R Gupta","year":"2022","unstructured":"Gupta R, Morten CJ, Zhu AY, Ramachandran R, Shah ND, Ross JS. Approvals and timing of new formulations of novel drugs approved by the US food and drug administration between 1995 and 2010 and followed through 2021. JAMA Health Forum. 2022;3:e221096\u2013e221096. https:\/\/doi.org\/10.1001\/jamahealthforum.2022.1096.","journal-title":"JAMA Health Forum"},{"key":"787_CR13","unstructured":"The United States Department of Justice. Justice Department Obtains $1.4 Billion from Reckitt Benckiser Group in Largest Recovery in a Case Concerning an Opioid Drug in United States History 2019. https:\/\/www.justice.gov\/opa\/pr\/justice-department-obtains-14-billion-reckitt-benckiser-group-largest-recovery-case (accessed March 22, 2022)."},{"key":"787_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/1073110519898042","volume":"47","author":"RL Haffajee","year":"2019","unstructured":"Haffajee RL, Frank RG. Generic drug policy and suboxone to treat opioid use disorder. J Law Med Ethics. 2019;47:43\u201353. https:\/\/doi.org\/10.1177\/1073110519898042.","journal-title":"J Law Med Ethics"},{"key":"787_CR15","unstructured":"Clemans-Cope L, Epstein M, Kenney GM. Rapid Growth in Medicaid Spending on Medications to Treat Opioid Use Disorder and Overdose 2017. https:\/\/www.urban.org\/sites\/default\/files\/publication\/91521\/2001386-rapid-growth-in-medicaid-spending-on-medications-to-treat-opioid-use-disorder-and-overdose_3.pdf (accessed June 21, 2022)."},{"key":"787_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/17411343211035168","volume":"18","author":"P Grootendorst","year":"2022","unstructured":"Grootendorst P. Brand drug companies impeding generic drug company access to product samples: estimated prevalence and impact on drug costs. J Gen Med. 2022;18:10\u201320. https:\/\/doi.org\/10.1177\/17411343211035168.","journal-title":"J Gen Med"},{"key":"787_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1503\/cmaj.140308","volume":"187","author":"EA Roberts","year":"2015","unstructured":"Roberts EA, Herder M, Hollis A. Fair pricing of \u201cold\u201d orphan drugs: considerations for Canada\u2019s orphan drug policy. CMAJ. 2015;187:422\u20135. https:\/\/doi.org\/10.1503\/cmaj.140308.","journal-title":"CMAJ"},{"key":"787_CR18","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jogc.2017.04.028","volume":"39","author":"A Ordean","year":"2017","unstructured":"Ordean A, Wong S, Graves L. No. 349-substance use in pregnancy. J Obstet Gynaecol Can. 2017;39:922\u201337. https:\/\/doi.org\/10.1016\/j.jogc.2017.04.028.","journal-title":"J Obstet Gynaecol Can"},{"key":"787_CR19","unstructured":"Health Canada. Drug Product Database: Access the database. Drug Product Database: Access the Database 2015. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/drug-product-database.html (accessed March 22, 2022)."},{"key":"787_CR20","unstructured":"Health Canada. Notice of Compliance search 2010. https:\/\/health-products.canada.ca\/noc-ac\/newSearch-nouvelleRecherche.do (accessed June 20, 2022)."},{"key":"787_CR21","unstructured":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations n.d. https:\/\/www.equator-network.org\/reporting-guidelines\/cheers\/ (accessed June 30, 2022)."},{"key":"787_CR22","unstructured":"Canadian Institute for Health Information. National Prescription Drug Utilization Information System metadata n.d."},{"key":"787_CR23","doi-asserted-by":"crossref","unstructured":"Government of Canada, Statistics Canada. Population estimates, quarterly 2022.","DOI":"10.1787\/da8d2bac-en"},{"key":"787_CR24","doi-asserted-by":"publisher","first-page":"26817","DOI":"10.1136\/bmjopen-2018-026817","volume":"9","author":"SR Chapman","year":"2019","unstructured":"Chapman SR, Aladul MI, Fitzpatrick RW. Lost cost savings to the NHS in England due to the delayed entry of multiple generic low-dose transdermal buprenorphine: a case scenario analysis. BMJ Open. 2019;9:26817. https:\/\/doi.org\/10.1136\/bmjopen-2018-026817.","journal-title":"BMJ Open"},{"key":"787_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.healthpol.2003.07.007","volume":"68","author":"J Lexchin","year":"2004","unstructured":"Lexchin J. The effect of generic competition on the price of brand-name drugs. Health Policy. 2004;68:47\u201354. https:\/\/doi.org\/10.1016\/j.healthpol.2003.07.007.","journal-title":"Health Policy"},{"key":"787_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","volume":"27","author":"AK Wagner","year":"2002","unstructured":"Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27:299\u2013309. https:\/\/doi.org\/10.1046\/j.1365-2710.2002.00430.x.","journal-title":"J Clin Pharm Ther"},{"key":"787_CR27","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1111\/j.1365-2753.2010.01504.x","volume":"17","author":"A Linden","year":"2011","unstructured":"Linden A, Adams JL. Applying a propensity score-based weighting model to interrupted time series data: improving causal inference in programme evaluation. J Eval Clin Pract. 2011;17:1231\u20138. https:\/\/doi.org\/10.1111\/j.1365-2753.2010.01504.x.","journal-title":"J Eval Clin Pract"},{"key":"787_CR28","unstructured":"The CIHR Canadian Research Initiative in Substance Misuse. CRISM national guideline for the clinical management of opioid use disorder. 2018."},{"key":"787_CR29","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1176\/appi.ps.201700315","volume":"69","author":"AW Roberts","year":"2018","unstructured":"Roberts AW, Saloner B, Dusetzina SB. Buprenorphine use and spending for opioid use disorder treatment: trends from 2003 to 2015. Psychiatr Serv. 2018;69:832\u20135. https:\/\/doi.org\/10.1176\/appi.ps.201700315.","journal-title":"Psychiatr Serv"},{"key":"787_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jval.2020.04.1840","volume":"24","author":"RE Barenie","year":"2021","unstructured":"Barenie RE, Sinha MS, Kesselheim AS. Factors affecting buprenorphine utilization and spending in Medicaid, 2002\u20132018. Value Health. 2021;24:182\u20137. https:\/\/doi.org\/10.1016\/j.jval.2020.04.1840.","journal-title":"Value Health"},{"key":"787_CR31","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/1468-0009.12279","volume":"95","author":"OJ Wouters","year":"2017","unstructured":"Wouters OJ, Kanavos PG, McKEE M. Comparing generic drug markets in Europe and the United States: prices, volumes, and spending. Milbank Q. 2017;95:554\u2013601. https:\/\/doi.org\/10.1111\/1468-0009.12279.","journal-title":"Milbank Q"},{"key":"787_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1430-9134.1997.00075.x","volume":"6","author":"RG Frank","year":"1997","unstructured":"Frank RG, Salkever DS. Generic entry and the pricing of pharmaceuticals. J Econ Manag Strategy. 1997;6:75\u201390. https:\/\/doi.org\/10.1111\/j.1430-9134.1997.00075.x.","journal-title":"J Econ Manag Strategy"},{"key":"787_CR33","unstructured":"Government of British Columbia. Low Cost Alternative (LCA) Program 2021. https:\/\/www2.gov.bc.ca\/gov\/content\/health\/practitioner-professional-resources\/pharmacare\/prescribers\/how-pharmacare-covers-drugs-in-the-low-cost-alternative-lca-program (accessed June 2, 2022)."},{"key":"787_CR34","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.sapharm.2017.08.001","volume":"14","author":"JN Howard","year":"2018","unstructured":"Howard JN, Harris I, Frank G, Kiptanui Z, Qian J, Hansen R. Influencers of generic drug utilization: a systematic review. Res Social Adm Pharm. 2018;14:619\u201327. https:\/\/doi.org\/10.1016\/j.sapharm.2017.08.001.","journal-title":"Res Social Adm Pharm"},{"key":"787_CR35","doi-asserted-by":"publisher","first-page":"59561","DOI":"10.1136\/bmjopen-2021-059561","volume":"12","author":"A Sud","year":"2022","unstructured":"Sud A, Strang M, Buchman DZ, Spithoff S, Upshur REG, Webster F, et al. How the suboxone education programme presented as a solution to risks in the Canadian opioid crisis: a critical discourse analysis. BMJ Open. 2022;12:59561. https:\/\/doi.org\/10.1136\/bmjopen-2021-059561.","journal-title":"BMJ Open"},{"key":"787_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamapsychiatry.2018.3685","volume":"76","author":"K Fiscella","year":"2019","unstructured":"Fiscella K, Wakeman SE, Beletsky L. Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X Waiver. JAMA Psychiat. 2019;76:229\u201330. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.3685.","journal-title":"JAMA Psychiat"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-022-00787-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-022-00787-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-022-00787-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T16:27:45Z","timestamp":1682008065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-022-00787-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["787"],"URL":"https:\/\/doi.org\/10.1007\/s40258-022-00787-0","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"28 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the Substance Use and Abuse Program, Health Canada (grant number 1920-HQ-000031).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the funder\/sponsor"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication (from patients\/participants)"}},{"value":"All data sources are available publicly through the Canadian Institute for Health Information or Health Canada.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Available upon request.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"RM and MM had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: All authors. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: All authors. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: RM, MM. Obtained funding: Sud. Administrative, technical, or material support: All authors. Supervision: Sud.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contributions"}}]}}